CA1311686C — Controlled release bioerodible drug delivery system
Assigned to Novartis AG · Expires 1992-12-22 · 33y expired
What this patent protects
CONTROLLED RELEASE BIOERODIBLE DRUG DELIVERY SYSTEM Abstract of the Disclosure A dosage composition for controlled release of a pharmaceutical compound to body fluids such as the tears of the eye, or surgical site fluids, has an external matrix rapidly soluble in said fluids,…
USPTO Abstract
CONTROLLED RELEASE BIOERODIBLE DRUG DELIVERY SYSTEM Abstract of the Disclosure A dosage composition for controlled release of a pharmaceutical compound to body fluids such as the tears of the eye, or surgical site fluids, has an external matrix rapidly soluble in said fluids, and bioerodible microparticles dispersed in the external matrix, the microparticles containing the pharmaceutical compound and being capable of releasing it gradually and in controlled fashion to the body fluids, and being of a size to be retained for a period of time long enough to provide an effective dose of the pharmaceutical compound to the site of placement for an extended period of time. The microparticles ultimately dissolve in the body fluids.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.